New drug combo for HER2 cancers shows early promise but trial ends early
NCT ID NCT04278144
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 19 times
Summary
This study tested a new drug called BDC-1001, alone or with another drug (nivolumab), in people with advanced HER2-positive cancers (like breast, stomach, or colon cancer) that no longer responded to standard treatments. The goal was to check safety and see if tumors shrank. The trial was stopped early, but results help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, Songpa-gu, 05505, South Korea
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Hospital Universitario 12 de Octubre
Madrid, Madrid, 28041, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, Madrid, 28034, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, Catalonia, 08035, Spain
-
Hospital del Mar
Barcelona, Catalonia, 08003, Spain
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut Paoli Calmettes
Marseille, 13009, France
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Samsung Medical Center
Seoul, Gangnam-gu, 06351, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620, South Korea
-
South Texas Accelerated Research Therapeutics
San Antonio, Texas, 78229, United States
-
Stanford University
Palo Alto, California, 94304, United States
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
The University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.